{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:45:25Z","timestamp":1785386725279,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s12328-020-01107-6","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T18:23:58Z","timestamp":1583259838000},"page":"860-866","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Destructive thyroiditis presenting as thyrotoxicosis followed by hypothyroidism during lenvatinib therapy for hepatocellular carcinoma"],"prefix":"10.1007","volume":"13","author":[{"given":"Maito","family":"Suoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"key":"1107_CR1","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.23131","volume":"122","author":"J Matsui","year":"2008","unstructured":"Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122:664\u201371.","journal-title":"Int J Cancer"},{"key":"1107_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2045-824X-6-18","volume":"6","author":"Y Yamamoto","year":"2014","unstructured":"Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18.","journal-title":"Vasc Cell"},{"key":"1107_CR3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"1107_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182\u2013236.","journal-title":"J Hepatol"},{"key":"1107_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723\u201350.","journal-title":"Hepatology"},{"key":"1107_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","volume":"52","author":"K Ikeda","year":"2017","unstructured":"Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2017;52:512\u20139.","journal-title":"J Gastroenterol"},{"key":"1107_CR7","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343\u2013421.","journal-title":"Thyroid"},{"key":"1107_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1620\/tjem.222.39","volume":"222","author":"K Sakurai","year":"2010","unstructured":"Sakurai K, Fukazawa H, Arihara Z, et al. Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume. Tohoku J Exp Med. 2010;222:39\u201344.","journal-title":"Tohoku J Exp Med"},{"key":"1107_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1089\/thy.2010.0234","volume":"21","author":"L van Doorn","year":"2011","unstructured":"van Doorn L, Eskens FA, Visser TJ, et al. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid. 2011;21:197\u2013202.","journal-title":"Thyroid"},{"key":"1107_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1089\/thy.2012.0456","volume":"23","author":"N Makita","year":"2013","unstructured":"Makita N, Iiri T. Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid. 2013;23:151\u20139.","journal-title":"Thyroid"},{"key":"1107_CR11","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1056\/NEJMra021194","volume":"348","author":"EN Pearce","year":"2003","unstructured":"Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348:2646\u201355.","journal-title":"N Engl J Med"},{"key":"1107_CR12","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2169\/internalmedicine.1874-18","volume":"58","author":"M Hirooka","year":"2019","unstructured":"Hirooka M, Ochi H, Hiraoka A, et al. Destructive thyroiditis induced by lenvatinib in three patients with hepatocellular carcinoma. Intern Med. 2019;58:791\u20135.","journal-title":"Intern Med"},{"key":"1107_CR13","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v.\u00a05.0. In: Division of cancer treatment and diagnosis, cancer therapy evaluation program, protocol development, adverse events\/CTCAE. 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 27 Oct 2019."},{"key":"1107_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1365-2265.2007.02832.x","volume":"67","author":"H Ota","year":"2007","unstructured":"Ota H, Amino N, Morita S, et al. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves\u2019 disease. Clin Endocrinol (Oxf). 2007;67:41\u20135.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1107_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4158\/EP.15.1.6","volume":"15","author":"KV Hari Kumar","year":"2009","unstructured":"Hari Kumar KV, Pasupuleti V, Jayaraman M, et al. Role of thyroid Doppler in differential diagnosis of thyrotoxicosis. Endocr Pract. 2009;15:6\u20139.","journal-title":"Endocr Pract"},{"key":"1107_CR16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.4329\/wjr.v5.i4.178","volume":"5","author":"RH Donkol","year":"2013","unstructured":"Donkol RH, Nada AM, Boughattas S. Role of color Doppler in differentiation of Graves\u2019 disease and thyroiditis in thyrotoxicosis. World J Radiol. 2013;5:178\u201383.","journal-title":"World J Radiol"},{"key":"1107_CR17","unstructured":"Eisai Co., Ltd. LENVIMA Interview Form, 8th edition (revised March 2019). In: Medical.eisai.jp, Drug Information. 2019. https:\/\/medical.eisai.jp\/content\/000004672.pdf. Accessed 27 Oct 2019 (in Japanese)."},{"key":"1107_CR18","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1507\/endocrj.EJ19-0140","volume":"66","author":"Y Koizumi","year":"2019","unstructured":"Koizumi Y, Hirooka M, Hiraoka A, et al. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma. Endocr J. 2019;66:787\u201392.","journal-title":"Endocr J"},{"key":"1107_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrclinonc.2009.4","volume":"6","author":"F Torino","year":"2009","unstructured":"Torino F, Corsello SM, Longo R, et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol. 2009;6:219\u201328.","journal-title":"Nat Rev Clin Oncol"},{"key":"1107_CR20","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ando.2018.07.003","volume":"79","author":"D Drui","year":"2018","unstructured":"Drui D, Illouz F, Do Cao C, et al. Expert opinion on thyroid complications of new anticancer therapies: tyrosine kinase inhibitors. Ann Endocrinol (Paris). 2018;79:569\u201373.","journal-title":"Ann Endocrinol (Paris)"},{"key":"1107_CR21","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/14740338.2018.1530212","volume":"17","author":"M Ikeda","year":"2018","unstructured":"Ikeda M, Kobayashi M, Tahara M, et al. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib. Expert Opin Drug Saf. 2018;17:1095\u2013105.","journal-title":"Expert Opin Drug Saf"},{"key":"1107_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/hepr.13427","volume":"50","author":"T Tada","year":"2020","unstructured":"Tada T, Kumada T, Hiraoka A, et al. Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: a multicenter analysis with propensity score matching. Hepatol Res. 2020;50:75\u201383.","journal-title":"Hepatol Res"},{"key":"1107_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13460","author":"T Hatanaka","year":"2019","unstructured":"Hatanaka T, Kakizaki S, Nagashima T, et al. Analyses of objective response, progression-free survival and adverse events in hepatocellular carcinoma patients treated with lenvatinib: a multicenter retrospective study. Hepatol Res. 2019. https:\/\/doi.org\/10.1111\/hepr.13460.","journal-title":"Hepatol Res"},{"key":"1107_CR24","doi-asserted-by":"publisher","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","volume":"290","author":"T Kamba","year":"2006","unstructured":"Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290:H560\u2013H576576.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1107_CR25","doi-asserted-by":"publisher","first-page":"12018","DOI":"10.1073\/pnas.1301331110","volume":"110","author":"Y Yang","year":"2013","unstructured":"Yang Y, Zhang Y, Cao Z, et al. Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc Natl Acad Sci USA. 2013;110:12018\u201323.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1107_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R. Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer. 2010;10:116\u201329.","journal-title":"Nat Rev Cancer"},{"key":"1107_CR27","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1177\/002215549704500710","volume":"45","author":"SE Hughes","year":"1997","unstructured":"Hughes SE. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem. 1997;45:1005\u2013199.","journal-title":"J Histochem Cytochem"},{"key":"1107_CR28","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1210\/en.2004-1134","volume":"146","author":"R St Bernard","year":"2005","unstructured":"St Bernard R, Zheng L, Liu W, et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology. 2005;146:1145\u201353.","journal-title":"Endocrinology"},{"key":"1107_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/sj.bjc.6606029","volume":"104","author":"N Shinohara","year":"2011","unstructured":"Shinohara N, Takahashi M, Kamishima T, et al. The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. Br J Cancer. 2011;104:241\u20137.","journal-title":"Br J Cancer"},{"key":"1107_CR30","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/j.ejrad.2011.06.035","volume":"81","author":"K Kitajima","year":"2012","unstructured":"Kitajima K, Takahashi S, Maeda T, et al. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: Comparison with thyroid function. Eur J Radiol. 2012;81:2060\u20135.","journal-title":"Eur J Radiol"},{"key":"1107_CR31","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00345-010-0627-2","volume":"29","author":"LM Riesenbeck","year":"2011","unstructured":"Riesenbeck LM, Bierer S, Hoffmeister I, et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol. 2011;29:807\u201313.","journal-title":"World J Urol"},{"key":"1107_CR32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.clgc.2012.08.002","volume":"10","author":"J Clemons","year":"2012","unstructured":"Clemons J, Gao D, Naam M, et al. Thyroid dysfunction in patients treated with sunitinib or sorafenib. Clin Genitourin Cancer. 2012;10:225\u201331.","journal-title":"Clin Genitourin Cancer"},{"key":"1107_CR33","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/cncr.25422","volume":"117","author":"M Schmidinger","year":"2011","unstructured":"Schmidinger M, Vogl UM, Bojic M, et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer. 2011;117:534\u201344.","journal-title":"Cancer"},{"key":"1107_CR34","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1210\/jc.2016-4025","volume":"102","author":"CM Beukhof","year":"2017","unstructured":"Beukhof CM, van Doorn L, Visser TJ, et al. Sorafenib-induced changes in thyroid hormone levels in patients treated for hepatocellular carcinoma. J Clin Endocrinol Metab. 2017;102:2922\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"1107_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360.","journal-title":"Semin Liver Dis"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-020-01107-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-020-01107-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-020-01107-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T01:27:51Z","timestamp":1614734871000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-020-01107-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,3]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1107"],"URL":"https:\/\/doi.org\/10.1007\/s12328-020-01107-6","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,3]]},"assertion":[{"value":"29 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Masaaki Inaba received lecture fees from Beyer and Pfizer. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human rights"}},{"value":"Informed consent was obtained from the patient for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}